Cargando…

Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines

In omics sciences, many compounds are measured simultaneously in a sample in a single run. Such analytical performance opens up prospects for improving cellular cancer vaccines and other cell-based immunotherapeutics. This article provides an overview of proteomics technology, known as cell proteomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lokhov, Petr G., Balashova, Elena E., Trifonova, Oxana P., Maslov, Dmitry L., Archakov, Alexander I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963030/
https://www.ncbi.nlm.nih.gov/pubmed/36839983
http://dx.doi.org/10.3390/pharmaceutics15020661
_version_ 1784896149945057280
author Lokhov, Petr G.
Balashova, Elena E.
Trifonova, Oxana P.
Maslov, Dmitry L.
Archakov, Alexander I.
author_facet Lokhov, Petr G.
Balashova, Elena E.
Trifonova, Oxana P.
Maslov, Dmitry L.
Archakov, Alexander I.
author_sort Lokhov, Petr G.
collection PubMed
description In omics sciences, many compounds are measured simultaneously in a sample in a single run. Such analytical performance opens up prospects for improving cellular cancer vaccines and other cell-based immunotherapeutics. This article provides an overview of proteomics technology, known as cell proteomic footprinting. The molecular phenotype of cells is highly variable, and their antigenic profile is affected by many factors, including cell isolation from the tissue, cell cultivation conditions, and storage procedures. This makes the therapeutic properties of cells, including those used in vaccines, unpredictable. Cell proteomic footprinting makes it possible to obtain controlled cell products. Namely, this technology facilitates the cell authentication and quality control of cells regarding their molecular phenotype, which is directly connected with the antigenic properties of cell products. Protocols for cell proteomic footprinting with their crucial moments, footprint processing, and recommendations for the implementation of this technology are described in this paper. The provided footprints in this paper and program source code for their processing contribute to the fast implementation of this technology in the development and manufacturing of cell-based immunotherapeutics.
format Online
Article
Text
id pubmed-9963030
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99630302023-02-26 Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines Lokhov, Petr G. Balashova, Elena E. Trifonova, Oxana P. Maslov, Dmitry L. Archakov, Alexander I. Pharmaceutics Review In omics sciences, many compounds are measured simultaneously in a sample in a single run. Such analytical performance opens up prospects for improving cellular cancer vaccines and other cell-based immunotherapeutics. This article provides an overview of proteomics technology, known as cell proteomic footprinting. The molecular phenotype of cells is highly variable, and their antigenic profile is affected by many factors, including cell isolation from the tissue, cell cultivation conditions, and storage procedures. This makes the therapeutic properties of cells, including those used in vaccines, unpredictable. Cell proteomic footprinting makes it possible to obtain controlled cell products. Namely, this technology facilitates the cell authentication and quality control of cells regarding their molecular phenotype, which is directly connected with the antigenic properties of cell products. Protocols for cell proteomic footprinting with their crucial moments, footprint processing, and recommendations for the implementation of this technology are described in this paper. The provided footprints in this paper and program source code for their processing contribute to the fast implementation of this technology in the development and manufacturing of cell-based immunotherapeutics. MDPI 2023-02-16 /pmc/articles/PMC9963030/ /pubmed/36839983 http://dx.doi.org/10.3390/pharmaceutics15020661 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lokhov, Petr G.
Balashova, Elena E.
Trifonova, Oxana P.
Maslov, Dmitry L.
Archakov, Alexander I.
Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines
title Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines
title_full Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines
title_fullStr Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines
title_full_unstemmed Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines
title_short Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines
title_sort cell proteomic footprinting: advances in the quality of cellular and cell-derived cancer vaccines
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963030/
https://www.ncbi.nlm.nih.gov/pubmed/36839983
http://dx.doi.org/10.3390/pharmaceutics15020661
work_keys_str_mv AT lokhovpetrg cellproteomicfootprintingadvancesinthequalityofcellularandcellderivedcancervaccines
AT balashovaelenae cellproteomicfootprintingadvancesinthequalityofcellularandcellderivedcancervaccines
AT trifonovaoxanap cellproteomicfootprintingadvancesinthequalityofcellularandcellderivedcancervaccines
AT maslovdmitryl cellproteomicfootprintingadvancesinthequalityofcellularandcellderivedcancervaccines
AT archakovalexanderi cellproteomicfootprintingadvancesinthequalityofcellularandcellderivedcancervaccines